Drug, across the briefings
Navtemadlin across 47 cancers
Navtemadlin appears in 47 of the briefings; no FDA label names any of them.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Acute lymphoblastic leukemia | phase 3 on TP53 | — | — | |
| Acute myeloid leukemia | phase 3 on TP53 | 4 | 2 | |
| Anal cancer | phase 3 on TP53 | — | — | |
| Basal cell carcinoma | phase 3 on TP53 | — | — | |
| Bladder cancer | phase 3 on TP53 | — | — | |
| Breast cancer | phase 3 on TP53 | — | — | |
| Burkitt lymphoma | phase 3 on TP53 | — | — | |
| Cervical cancer | phase 3 on TP53 | — | — | |
| Cholangiocarcinoma | phase 3 on TP53 | — | — | |
| Chronic lymphocytic leukemia | phase 3 on TP53 | 2 | 1 | |
| Chronic myeloid leukemia | phase 3 on TP53 | 1 | 0 | |
| Colorectal cancer | phase 3 on TP53 | — | — | |
| Cutaneous squamous cell carcinoma | phase 3 on TP53 | — | — | |
| Diffuse large B-cell lymphoma | phase 3 on TP53 | 2 | 1 | |
| Endometrial cancer | phase 3 on TP53 | 1 | 1 | |
| Esophageal cancer | phase 3 on TP53 | — | — | |
| Ewing sarcoma | phase 3 on TP53 | — | — | |
| Gallbladder cancer | phase 3 on TP53 | — | — | |
| Gastric cancer | phase 3 on TP53 | — | — | |
| Gastrointestinal stromal tumour | phase 3 on TP53 | — | — | |
| Glioblastoma | phase 3 on TP53, MDM2 | 1 | 0 | |
| Head and neck cancer | phase 3 on TP53 | — | — | |
| Hepatocellular carcinoma | phase 3 on TP53 | — | — | |
| Lower-grade glioma | phase 3 on TP53 | — | — | |
| Lung cancer | phase 3 on TP53 | 2 | 0 | |
| Mantle cell lymphoma | phase 3 on TP53 | 1 | 0 | |
| Marginal zone lymphoma | phase 3 on TP53 | — | — | |
| Medulloblastoma | phase 3 on TP53 | — | — | |
| Merkel cell carcinoma | phase 3 on TP53 | 1 | 0 | |
| Mesothelioma | phase 3 on TP53 | — | — | |
| Multiple myeloma | phase 3 on TP53 | 1 | 0 | |
| Myelodysplastic syndromes | phase 3 on TP53 | 1 | 1 | |
| Myeloproliferative neoplasms | phase 3 on TP53 | 7 | 2 | |
| Nasopharyngeal carcinoma | phase 3 on TP53 | — | — | |
| Osteosarcoma | phase 3 on TP53, MDM2 | — | — | |
| Ovarian cancer | phase 3 on TP53 | — | — | |
| Pancreatic cancer | phase 3 on TP53 | — | — | |
| Prostate cancer | phase 3 on TP53 | — | — | |
| Rhabdomyosarcoma | phase 3 on TP53, MDM2 | — | — | |
| Small cell lung cancer | phase 3 on TP53 | 1 | 0 | |
| Small intestine cancer | phase 3 on TP53 | — | — | |
| Soft tissue sarcoma | phase 3 on TP53, MDM2 | 1 | 0 | |
| Testicular cancer | phase 3 on TP53, MDM2 | — | — | |
| Thyroid cancer | phase 3 on TP53 | — | — | |
| Vulvar cancer | phase 3 on TP53 | — | — | |
| Waldenström macroglobulinaemia | phase 3 on TP53 | — | — | |
| Wilms tumour | phase 3 on TP53 | — | — |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.